Evaluation of myelographic contrast-medium tolerance with psychometric testing

Area of Science:

• Radiology
• Neuroscience
• Pharmacology

Background:

• Myelography is a diagnostic imaging procedure that uses contrast media.
• Assessing the clinical tolerance and potential adverse effects of these agents is crucial.
• Metrizamide and iopamidol are commonly used myelographic contrast media with varying reported side effect profiles.

Purpose of the Study:

• To evaluate and compare the clinical tolerance of metrizamide and iopamidol using neuropsychologic testing.
• To identify sensitive measures for detecting subtle adverse reactions to contrast media.
• To correlate adverse reactions with the dose of contrast medium administered.

Main Methods:

• A randomized, double-blind, prospective study involving 26 patients receiving metrizamide and 30 patients receiving iopamidol.
• Neuropsychologic tests assessing conceptual reasoning and affect were administered before and after myelography.
• A control group of 20 patients undergoing computed tomography without contrast was included.

Main Results:

• Neuropsychologic tests sensitive to conceptual reasoning and affect identified adverse reactions.
• Somatic side effects occurred in 38% of patients receiving metrizamide versus 17% receiving iopamidol.
• Adverse reactions paralleled somatic reactions and correlated with contrast medium dose.

Conclusions:

• Neuropsychologic testing is a sensitive method for detecting subtle adverse reactions to myelographic contrast media.
• Iopamidol demonstrates better clinical tolerance compared to metrizamide.
• Further refinement of control groups and testing intervals is recommended for future studies.